Literature DB >> 19775091

Human liver microsomal metabolism of (+)-discodermolide.

Yun Fan1, Emanuel M Schreiber, Billy W Day.   

Abstract

The polyketide natural product (+)-discodermolide is a potent microtubule stabilizer that has generated considerable interest in its synthetic, medicinal, and biological chemistry. It progressed to early clinical oncology trials, where it showed some efficacy in terms of disease stabilization but also some indications of causing pneumotoxicity. Remarkably, there are no reports of its metabolism. Here, we examined its fate in mixed human liver microsomes. Due to limited availability of the agent, we chose a nanoflow liquid chromatography-electrospray ionization-mass spectrometry analytical approach employing quadrupolar ion trap and quadrupole-quadrupole-time-of-flight instruments for these studies. (+)-Discodermolide was rapidly converted to eight metabolites, with the left-side lactone (net oxidation) and the right-side diene (epoxidation followed by hydrolysis, along with an oxygen insertion product) being the most metabolically labile sites. Other sites of metabolism were the allylic and pendant methyl moieties in the C12-C14 region of the molecule. The results provide information on the metabolic soft spots of the molecule and can be used in further medicinal chemistry efforts to optimize discodermolide analogues.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19775091      PMCID: PMC2768424          DOI: 10.1021/np900245k

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  15 in total

1.  Solution structure of (+)-discodermolide.

Authors:  A B Smith; M J LaMarche; M Falcone-Hindley
Journal:  Org Lett       Date:  2001-03-08       Impact factor: 6.005

2.  Toward understanding how the lactone moiety of discodermolide affects activity.

Authors:  Simon J Shaw; Kurt F Sundermann; Mark A Burlingame; David C Myles; B Scott Freeze; Ming Xian; Ignacio Brouard; Amos B Smith
Journal:  J Am Chem Soc       Date:  2005-05-11       Impact factor: 15.419

3.  The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.

Authors:  R J Kowalski; P Giannakakou; S P Gunasekera; R E Longley; B W Day; E Hamel
Journal:  Mol Pharmacol       Date:  1997-10       Impact factor: 4.436

4.  Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity.

Authors:  Rubén M Buey; Isabel Barasoain; Evelyn Jackson; Arndt Meyer; Paraskevi Giannakakou; Ian Paterson; Susan Mooberry; José M Andreu; J Fernando Díaz
Journal:  Chem Biol       Date:  2005-12

5.  (+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest.

Authors:  D T Hung; J Chen; S L Schreiber
Journal:  Chem Biol       Date:  1996-04

Review 6.  Immunosuppression by discodermolide.

Authors:  R E Longley; S P Gunasekera; D Faherty; J Mclane; F Dumont
Journal:  Ann N Y Acad Sci       Date:  1993-11-30       Impact factor: 5.691

7.  Discodermolide--a new, marine-derived immunosuppressive compound. II. In vivo studies.

Authors:  R E Longley; D Caddigan; D Harmody; M Gunasekera; S P Gunasekera
Journal:  Transplantation       Date:  1991-10       Impact factor: 4.939

8.  Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol.

Authors:  E ter Haar; R J Kowalski; E Hamel; C M Lin; R E Longley; S P Gunasekera; H S Rosenkranz; B W Day
Journal:  Biochemistry       Date:  1996-01-09       Impact factor: 3.162

9.  Semisynthetic analogues of the microtubule-stabilizing agent discodermolide: preparation and biological activity.

Authors:  Sarath P Gunasekera; Ross E Longley; Richard A Isbrucker
Journal:  J Nat Prod       Date:  2002-12       Impact factor: 4.050

10.  Discodermolide--a new, marine-derived immunosuppressive compound. I. In vitro studies.

Authors:  R E Longley; D Caddigan; D Harmody; M Gunasekera; S P Gunasekera
Journal:  Transplantation       Date:  1991-10       Impact factor: 4.939

View more
  6 in total

1.  Structural Refinement of the Tubulin Ligand (+)-Discodermolide to Attenuate Chemotherapy-Mediated Senescence.

Authors:  Boying Guo; Alicia Rodriguez-Gabin; Andrea E Prota; Tobias Mühlethaler; Nan Zhang; Kenny Ye; Michel O Steinmetz; Susan Band Horwitz; Amos B Smith; Hayley M McDaid
Journal:  Mol Pharmacol       Date:  2020-06-26       Impact factor: 4.436

2.  A simplified synthesis of novel dictyostatin analogues with in vitro activity against epothilone B-resistant cells and antiangiogenic activity in zebrafish embryos.

Authors:  Laura L Vollmer; Maria Jiménez; Daniel P Camarco; Wei Zhu; Hikmat N Daghestani; Raghavan Balachandran; Celeste E Reese; John S Lazo; Neil A Hukriede; Dennis P Curran; Billy W Day; Andreas Vogt
Journal:  Mol Cancer Ther       Date:  2011-04-13       Impact factor: 6.261

3.  Metabolic study of Angelica dahurica extracts using a reusable liver microsomal nanobioreactor by liquid chromatography-mass spectrometry.

Authors:  Hai-Li Shi; Yan-Wei Jia; Shu-Lin Peng; Xun Liao; Li-Sheng Ding; Yi-Ming Liu
Journal:  Biomed Chromatogr       Date:  2015-03-08       Impact factor: 1.902

4.  Streamlined syntheses of (-)-dictyostatin, 16-desmethyl-25,26-dihydrodictyostatin, and 6-epi-16-desmethyl-25,26-dihydrodictyostatin.

Authors:  Wei Zhu; María Jiménez; Won-Hyuk Jung; Daniel P Camarco; Raghavan Balachandran; Andreas Vogt; Billy W Day; Dennis P Curran
Journal:  J Am Chem Soc       Date:  2010-07-07       Impact factor: 15.419

5.  Synthesis of (+)-discodermolide by catalytic stereoselective borylation reactions.

Authors:  Zhiyong Yu; Robert J Ely; James P Morken
Journal:  Angew Chem Int Ed Engl       Date:  2014-07-15       Impact factor: 15.336

6.  Design and synthesis of (+)-discodermolide-paclitaxel hybrids leading to enhanced biological activity.

Authors:  Amos B Smith; Keizo Sugasawa; Onur Atasoylu; Chia-Ping Huang Yang; Susan Band Horwitz
Journal:  J Med Chem       Date:  2011-08-26       Impact factor: 7.446

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.